AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is currently conducting a national multicenter non-interventional study titled ‘National Multicentre Non-interventional Study to Assess CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia.’ The study aims to evaluate the patterns and short-term outcomes of chemo-radiation therapy (CRT) in patients with unresectable non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in Russia, involving 2000 patients across 50 oncology centers.
The study focuses on CRT, a combination of chemotherapy and radiation therapy, intended to treat patients with locally advanced NSCLC and limited-stage SCLC. The study does not include specific treatments following CRT, such as durvalumab.
This observational study uses a cohort model with a prospective time perspective. It involves secondary data collection from existing medical records, with data gathered at the start and completion of CRT, ensuring compliance with local regulatory requirements.
The study began on March 31, 2023, with an estimated completion date in 2025. The latest update was submitted on August 11, 2025, indicating ongoing recruitment and data collection.
The study’s findings could influence AstraZeneca’s stock performance by providing insights into CRT’s effectiveness in routine practice, potentially impacting investor sentiment. It may also affect the competitive landscape in oncology treatment, particularly in the Russian market.
The study is ongoing, and further details are available on the ClinicalTrials portal.